Dafer Rima M, Biller José
Loyola University Chicago Stritch School of Medicine, Department of Neurology, Maywood, IL 60163, USA.
Expert Rev Neurother. 2007 Apr;7(4):333-7. doi: 10.1586/14737175.7.4.333.
Desmoteplase, developed by Paion, Forest and Lundbeck, is a novel plasminogen activator that selectively activates fibrin-bound plasminogen and is currently being investigated for the treatment of acute ischemic stroke within the time window of 3-9 h after symptom onset. Desmoteplase is believed to offer pharmacologic advantages over currently approved treatment options. To date, two published Phase II perfusion imaging-based clinical trials have reported the safety and potential efficacy of desmoteplase in ischemic stroke. Results from a recently completed Phase III trial in Europe, Asia and the USA are awaited. This article reviews the available data on desmoteplase, including discussion of its favorable features and potential benefit beyond the 3-h time window in the treatment of ischemic stroke.
由派昂（Paion）、福瑞斯特（Forest）和灵北（Lundbeck）公司研发的去氨普酶，是一种新型纤溶酶原激活剂，它能选择性激活与纤维蛋白结合的纤溶酶原，目前正处于研究阶段，用于治疗症状发作后3至9小时时间窗内的急性缺血性中风。人们认为去氨普酶比目前已获批的治疗方案具有药理学优势。迄今为止，两项已发表的基于灌注成像的II期临床试验报告了去氨普酶治疗缺血性中风的安全性和潜在疗效。欧洲、亚洲和美国最近完成的一项III期试验结果尚待公布。本文综述了关于去氨普酶的现有数据，包括对其有利特征以及在治疗缺血性中风时超出3小时时间窗的潜在益处的讨论。
